On 1 July 2026, The Korea Biomedical Review reported that Samsung Epis Holdings has opened and commenced operating its new research and development centre in Beijing. The establishment of the new R&D centre was first announced by Samsung Epis on 29 May 2026.
The R&D centre is operated by Samsung Bioepis (China), a wholly owned subsidiary of Samsung Epis Holdings, and will serve as a global R&D hub supported by “world-class scientific talent and advanced technological infrastructure in China”. The centre will have a strategic focus on securing antibody-drug conjugate (ADC) technology platforms and strengthening Samsung’s capabilities in new drug development.